Difference between revisions of "Malignant solid neoplasm, ERBB3-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "7 PubMed" to "7/ PubMed") |
Warner-admin (talk | contribs) m (Text replacement - "(NCT[0-9]{8})" to "[https://clinicaltrials.gov/ct2/show/$1 Clinical Trial Registry]") |
||
| Line 41: | Line 41: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # '''SUMMIT:''' Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 8;554(7691):189-194. Epub 2018 Jan 31. [https://www.nature.com/articles/nature25475 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808581/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29420467/ PubMed] NCT01953926 | + | # '''SUMMIT:''' Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 8;554(7691):189-194. Epub 2018 Jan 31. [https://www.nature.com/articles/nature25475 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808581/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29420467/ PubMed] [https://clinicaltrials.gov/ct2/show/NCT01953926 Clinical Trial Registry] |
[[Category:ERBB3 (HER3) regimens]] | [[Category:ERBB3 (HER3) regimens]] | ||
Revision as of 15:12, 31 May 2023
1 regimens on this page
1 variants on this page
|
All lines of therapy
Neratinib monotherapy
Regimen
| Study | Evidence |
|---|---|
| Hyman et al. 2018 (SUMMITHER) | Non-randomized basket trial, <20 pts in this subgroup |
Note: the cycle length is not described in the manuscript; the authors have clarified that the cycles are 28 days in length. This trial should not be confused with the one by the same name in multiple myeloma.
Biomarker eligibility criteria
- Gene: HER3
- Alteration: various substitutions
- Acceptable methods of measurement: next-generation sequencing assay or RT-PCR, Sanger, pyrosequencing, or mass spectrometry-based sequencing methods
Prior treatment criteria
- No prior treatment with HER kinase inhibitors
Targeted therapy
- Neratinib (Nerlynx) 240 mg PO once per day
Supportive therapy
- Loperamide (Imodium) (dose not specified) mandatory during cycle 1
28-day cycles
References
- SUMMIT: Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 8;554(7691):189-194. Epub 2018 Jan 31. link to original article contains dosing details in manuscript link to PMC article PubMed Clinical Trial Registry